MedTrace Logo

Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy

NCT00509574 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2010-12-13

No results posted yet for this study

Summary

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as statins, played an important role in lipid-lowering therapy and reduction of cardiovascular risks. However, it has been observed that the response to statin therapy varies from patient to patient, and gene polymorphism could have contributed to the variation.

Conditions

  • Statins, HMG-CoA
  • Single Nucleotide Polymorphism

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Tzung-Dau Wang, MD, PhD · Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Completion
2010-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509574 on ClinicalTrials.gov